US6100071A
(en)
|
1996-05-07 |
2000-08-08 |
Genentech, Inc. |
Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
|
US7070959B1
(en)
*
|
1999-06-08 |
2006-07-04 |
Regeneron Pharmaceuticals, Inc. |
Modified chimeric polypeptides with improved pharmacokinetic properties
|
US7087411B2
(en)
*
|
1999-06-08 |
2006-08-08 |
Regeneron Pharmaceuticals, Inc. |
Fusion protein capable of binding VEGF
|
WO2005069906A2
(en)
*
|
2004-01-16 |
2005-08-04 |
Yale University |
Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases
|
WO2005087808A2
(en)
|
2004-03-05 |
2005-09-22 |
Ludwig Institute For Cancer Research |
Growth factor binding constructs materials and methods
|
WO2005123104A2
(en)
|
2004-06-10 |
2005-12-29 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitors for the treatment of human cancer
|
ES2407859T3
(es)
|
2004-09-13 |
2013-06-14 |
Genzyme Corporation |
Construcciones multiméricas.
|
US8048418B2
(en)
|
2004-10-29 |
2011-11-01 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
|
US20080107648A1
(en)
*
|
2005-12-16 |
2008-05-08 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic methods for inhibiting tumor growth with DII4 antagonists
|
US20060134121A1
(en)
*
|
2004-10-29 |
2006-06-22 |
Gavin Thurston |
DII4 antagonists, assays, and therapeutic methods thereof
|
FR2878749B1
(fr)
*
|
2004-12-03 |
2007-12-21 |
Aventis Pharma Sa |
Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
|
CA2597247A1
(en)
|
2005-02-11 |
2006-08-17 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
|
US20060217311A1
(en)
*
|
2005-03-25 |
2006-09-28 |
Daniel Dix |
VEGF antagonist formulations
|
JP2009504679A
(ja)
*
|
2005-08-12 |
2009-02-05 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Vegfアンタゴニストを用いて疾患を処置する方法
|
US8329866B2
(en)
*
|
2005-10-03 |
2012-12-11 |
Bolder Biotechnology, Inc. |
Long acting VEGF inhibitors and methods of use
|
FR2895258B1
(fr)
*
|
2005-12-22 |
2008-03-21 |
Aventis Pharma Sa |
Combinaison comprenant de la combretastatine et des agents anticancereux
|
US8216575B2
(en)
*
|
2006-03-31 |
2012-07-10 |
Chengdu Kanghong Biotechnologies Co., Ltd. |
Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
|
CN100502945C
(zh)
*
|
2006-03-31 |
2009-06-24 |
成都康弘生物科技有限公司 |
Vegf受体融合蛋白在治疗眼睛疾病中的应用
|
WO2007149334A2
(en)
|
2006-06-16 |
2007-12-27 |
Regeneron Pharmaceuticals, Inc. |
Vegf antagonist formulations suitable for intravitreal administration
|
WO2008005290A2
(en)
*
|
2006-06-29 |
2008-01-10 |
The Trustees Of Columbia University In The City Of New York |
Methods for testing anti-thrombotic agents
|
EP2572734B1
(en)
|
2006-10-31 |
2016-04-06 |
East Carolina University |
Cytokine-based fusion proteins for treatment of immune disorders
|
RU2549676C2
(ru)
|
2007-06-01 |
2015-04-27 |
Юниверсити Оф Мэрилэнд, Балтимор |
СРЕДСТВА НА ОСНОВЕ КОНСТАНТНОЙ ОБЛАСТИ ИММУНОГЛОБУЛИНА СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР
|
TWI436775B
(zh)
|
2007-08-24 |
2014-05-11 |
Oncotherapy Science Inc |
以抗原胜肽合併化療藥劑治療胰臟癌
|
BRPI0910482A2
(pt)
|
2008-04-29 |
2019-09-24 |
Abbott Lab |
imunoglobinas de domínio variável duplo e usos das mesmas
|
EP2297209A4
(en)
|
2008-06-03 |
2012-08-01 |
Abbott Lab |
IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
|
CN102272148A
(zh)
*
|
2008-11-03 |
2011-12-07 |
分子组合公司 |
抑制vegf-a受体相互作用的结合蛋白
|
EP2727996A1
(en)
*
|
2008-11-06 |
2014-05-07 |
The Johns-Hopkins University |
Treatment of chronic inflammatory respiratory disorders with NP1 inhibitors
|
EP3348275A3
(en)
|
2009-03-31 |
2018-10-24 |
East Carolina University |
Cytokines and neuroantigens for treatment of immune disorders
|
JP2012525415A
(ja)
*
|
2009-05-01 |
2012-10-22 |
オプソテツク・コーポレイシヨン |
眼科疾患を処置または予防するための方法
|
JO3182B1
(ar)
|
2009-07-29 |
2018-03-08 |
Regeneron Pharma |
مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
|
EP2571992B1
(en)
*
|
2010-05-21 |
2018-04-25 |
Merrimack Pharmaceuticals, Inc. |
Bi-specific fusion proteins
|
UY33492A
(es)
|
2010-07-09 |
2012-01-31 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN103154036B
(zh)
|
2010-07-28 |
2016-05-11 |
格利克尼克股份有限公司 |
天然人蛋白片段的融合蛋白以产生有序多聚化免疫球蛋白fc组合物
|
PE20131412A1
(es)
|
2010-08-03 |
2014-01-19 |
Abbvie Inc |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
HUE035554T2
(en)
|
2010-08-06 |
2018-05-02 |
Genzyme Corp |
VEGF antagonist compositions and their uses
|
WO2012064792A2
(en)
*
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
AU2012205599B2
(en)
|
2011-01-13 |
2016-10-20 |
Regeneron Pharmaceuticals, Inc. |
Use of a VEGF antagonist to treat angiogenic eye disorders
|
JO3283B1
(ar)
|
2011-04-26 |
2018-09-16 |
Sanofi Sa |
تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
|
EP3415533A1
(en)
|
2011-08-19 |
2018-12-19 |
Regeneron Pharmaceuticals, Inc. |
Anti-tie2 antibodies uses thereof
|
US9701731B2
(en)
|
2011-08-19 |
2017-07-11 |
Children's Medical Center Corporation |
VEGF-binding protein for blockade of angiogenesis
|
JP6271432B2
(ja)
|
2011-09-30 |
2018-01-31 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗ErbB3抗体およびその使用
|
JO3370B1
(ar)
*
|
2011-11-10 |
2019-03-13 |
Regeneron Pharma |
طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
|
CN103957898B
(zh)
|
2011-11-18 |
2016-02-24 |
瑞泽恩制药公司 |
聚合物蛋白微粒
|
CA2857168C
(en)
*
|
2011-12-01 |
2020-10-27 |
Protevobio, Inc. |
Protein inhibitors to complement and vegf pathways and methods of use thereof
|
TWI613215B
(zh)
|
2012-02-22 |
2018-02-01 |
再生元醫藥公司 |
抗-大-內皮素-1(big-et-1)抗體及其用途
|
NZ631565A
(en)
|
2012-03-14 |
2016-07-29 |
Regeneron Pharma |
Multispecific antigen-binding molecules and uses thereof
|
TWI775096B
(zh)
|
2012-05-15 |
2022-08-21 |
澳大利亞商艾佛蘭屈澳洲私營有限公司 |
使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd)
|
TW201843172A
(zh)
|
2012-06-25 |
2018-12-16 |
美商再生元醫藥公司 |
抗-egfr抗體及其用途
|
CN104718223A
(zh)
|
2012-08-20 |
2015-06-17 |
格利克尼克股份有限公司 |
具有抗原结合和多价FCγ受体结合活性的分子
|
RU2542385C2
(ru)
*
|
2012-08-31 |
2015-02-20 |
Общество с ограниченной ответственностью "НекстГен" |
Способ получения фармацевтической композиции для индукции развития кровеносных сосудов в тканях, фармацевтическая композиция, полученная этим способом, и способ лечения ишемии тканей и/или органов человека
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
US20140134189A1
(en)
|
2012-11-13 |
2014-05-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-prokineticin receptor (prokr) antibodies and uses thereof
|
JO3405B1
(ar)
|
2013-01-09 |
2019-10-20 |
Regeneron Pharma |
الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
|
EP2956476B1
(en)
*
|
2013-02-18 |
2019-12-25 |
Vegenics Pty Limited |
Ligand binding molecules and uses thereof
|
CA2904644C
(en)
|
2013-03-14 |
2022-09-20 |
Regeneron Pharmaceuticals, Inc. |
Human antibodies to grem1
|
AR095196A1
(es)
|
2013-03-15 |
2015-09-30 |
Regeneron Pharma |
Medio de cultivo celular libre de suero
|
KR102049990B1
(ko)
|
2013-03-28 |
2019-12-03 |
삼성전자주식회사 |
c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
|
CN105431204A
(zh)
|
2013-07-12 |
2016-03-23 |
奥普索特克公司 |
用于治疗或预防眼科病的方法
|
KR102060187B1
(ko)
|
2013-07-19 |
2019-12-27 |
삼성전자주식회사 |
Vegf-c, vegf-d 및/또는 안지오포이에틴-2를 동시에 저해하는 융합 폴리펩타이드 및 이의 용도
|
WO2015058369A1
(en)
*
|
2013-10-23 |
2015-04-30 |
Sanofi (China) Investment Co., Ltd. |
Use of aflibercept and docetaxel for the treatment of nasopharyngeal carcinoma
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JP6632984B2
(ja)
|
2014-03-11 |
2020-01-22 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. |
抗EGFRvIII抗体およびその使用
|
CN106414474B
(zh)
|
2014-03-17 |
2021-01-15 |
阿德夫拉姆生物技术股份有限公司 |
用于视锥细胞中增强的基因表达的组合物和方法
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
EA035674B1
(ru)
|
2014-07-18 |
2020-07-24 |
Санофи |
Способ определения того, является ли пациент, предположительно страдающий от рака, кандидатом для терапии афлиберцептом
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
DK3221359T3
(da)
|
2014-11-17 |
2020-06-22 |
Regeneron Pharma |
Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
|
US20160144025A1
(en)
*
|
2014-11-25 |
2016-05-26 |
Regeneron Pharmaceuticals, Inc. |
Methods and formulations for treating vascular eye diseases
|
MY187898A
(en)
|
2015-03-02 |
2021-10-27 |
Adverum Biotechnologies Inc |
Compositions and methods for intravitreal delivery of polynucleotides to retinal cones
|
TW202336236A
(zh)
|
2015-03-27 |
2023-09-16 |
美商再生元醫藥公司 |
偵測生物污染物之組成物及方法
|
EP3273998B1
(en)
|
2015-03-27 |
2019-09-04 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
AU2016253005B2
(en)
*
|
2015-04-23 |
2020-07-09 |
Hemanext Inc. |
Anaerobic blood storage containers
|
PL3294775T3
(pl)
*
|
2015-05-12 |
2021-12-13 |
Regeneron Pharmaceuticals, Inc. |
Oznaczanie czystości białka multimerycznego
|
RU2612497C2
(ru)
|
2015-05-26 |
2017-03-09 |
Общество с ограниченной ответственностью "НекстГен" |
Оптимизированная нуклеотидная последовательность и фармацевтическая композиция на ее основе с пролонгированной экспрессией трансгена vegf
|
JOP20160154B1
(ar)
|
2015-07-31 |
2021-08-17 |
Regeneron Pharma |
أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
|
TWI797060B
(zh)
|
2015-08-04 |
2023-04-01 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017053856A1
(en)
|
2015-09-23 |
2017-03-30 |
Regeneron Pharmaceuticals, Inc. |
Optimized anti-cd3 bispecific antibodies and uses thereof
|
EP3355910A4
(en)
|
2015-09-28 |
2019-08-28 |
East Carolina University |
ALUMINUM-BASED ADJUVANTS FOR TOLEROGENIC VACCINATION
|
CA3000742A1
(en)
|
2015-10-02 |
2017-04-06 |
Silver Creek Pharmaceuticals, Inc. |
Bi-specific therapeutic proteins for tissue repair
|
TWI756187B
(zh)
|
2015-10-09 |
2022-03-01 |
美商再生元醫藥公司 |
抗lag3抗體及其用途
|
WO2017070866A1
(zh)
*
|
2015-10-28 |
2017-05-04 |
黄志清 |
一种抗血管内皮生长因子的氧化石墨烯与其用途
|
CA3005391A1
(en)
*
|
2015-11-19 |
2017-05-26 |
Zhuhai Tairuishang Biopharm Ltd. |
Methods and compositions for binding vegf
|
CA3137326C
(en)
|
2015-12-03 |
2024-01-23 |
Regeneron Pharmaceuticals, Inc. |
Use of vegf inhibitor to treat macular degeneration in a patient population
|
MA43416A
(fr)
|
2015-12-11 |
2018-10-17 |
Regeneron Pharma |
Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
|
AU2016369557B2
(en)
|
2015-12-16 |
2022-10-20 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods of manufacturing protein microparticles
|
HRP20231156T1
(hr)
|
2015-12-22 |
2024-01-05 |
Regeneron Pharmaceuticals, Inc. |
Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka
|
GB2545763A
(en)
|
2015-12-23 |
2017-06-28 |
Adverum Biotechnologies Inc |
Mutant viral capsid libraries and related systems and methods
|
AU2017211120C1
(en)
|
2016-01-25 |
2021-10-07 |
Regeneron Pharmaceuticals, Inc. |
Maytansinoid derivatives, conjugates thereof, and methods of use
|
EP3448891A1
(en)
|
2016-04-28 |
2019-03-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
US20190142975A1
(en)
|
2016-04-29 |
2019-05-16 |
Adverum Biotechnologies, Inc. |
Evasion of neutralizing antibodies by a recombinant adeno-associated virus
|
TWI822521B
(zh)
|
2016-05-13 |
2023-11-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
WO2017214321A1
(en)
|
2016-06-07 |
2017-12-14 |
Gliknik Inc. |
Cysteine-optimized stradomers
|
CN109563170B
(zh)
|
2016-06-10 |
2023-10-13 |
瑞泽恩制药公司 |
抗gitr抗体及其用途
|
SG11201900192VA
(en)
|
2016-07-29 |
2019-02-27 |
Regeneron Pharma |
Assembly line with integrated electronic visual inspection
|
IL264631B2
(en)
|
2016-08-16 |
2024-05-01 |
Regeneron Pharma |
A method for quantifying individual antibodies from a mixture
|
FI3761035T3
(fi)
|
2016-08-18 |
2024-03-18 |
Regeneron Pharma |
Analyysi proteiinin itseassosiaatiomahdollisuuden määrittämiseksi käyttäen pitoisuudesta riippuvaa itseinteraktio-nanopartikkelispektroskopiaa
|
WO2018039499A1
(en)
|
2016-08-24 |
2018-03-01 |
Regeneron Pharmaceuticals, Inc. |
Host cell protein modification
|
JP7066691B2
(ja)
|
2016-09-23 |
2022-05-13 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
二重特異性抗muc16-cd3抗体および抗muc16薬物複合体
|
US10772972B2
(en)
|
2016-09-23 |
2020-09-15 |
Regeneron Pharmaceuticals, Inc. |
Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
|
WO2018068012A1
(en)
|
2016-10-07 |
2018-04-12 |
Regeneron Pharmaceuticals, Inc. |
Room temperature stable lyophilized protein
|
AU2017345470B2
(en)
|
2016-10-19 |
2023-08-03 |
Adverum Biotechnologies, Inc. |
Modified AAV capsids and uses thereof
|
AU2017350807B2
(en)
|
2016-10-25 |
2022-07-07 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for chromatography data analysis
|
TWI782930B
(zh)
|
2016-11-16 |
2022-11-11 |
美商再生元醫藥公司 |
抗met抗體,結合met之雙特異性抗原結合分子及其使用方法
|
CN116327963A
(zh)
|
2016-11-21 |
2023-06-27 |
济世-伊沃泰克生物制品有限公司 |
一种眼科制剂及其用途
|
CA3044534A1
(en)
|
2016-11-29 |
2018-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating prlr positive breast cancer
|
MX2019006573A
(es)
|
2016-12-09 |
2019-11-18 |
Gliknik Inc |
Optimizacion de fabricacion de gl-2045 un stradomer multimerizante.
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
SG11201907208XA
(en)
|
2017-02-10 |
2019-09-27 |
Regeneron Pharma |
Radiolabeled anti-lag3 antibodies for immuno-pet imaging
|
CN117442719A
(zh)
|
2017-02-21 |
2024-01-26 |
瑞泽恩制药公司 |
用于治疗肺癌的抗pd-1抗体
|
SG11201907653QA
(en)
|
2017-03-17 |
2019-09-27 |
Adverum Biotechnologies Inc |
Compositions and methods for enhanced gene expression
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
CA3062418A1
(en)
|
2017-05-06 |
2018-11-15 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating eye disorders with aplnr antagonists and vegf inhibitors
|
BR112019027211A2
(pt)
|
2017-06-28 |
2020-06-30 |
Regeneron Pharmaceuticals, Inc. |
proteínas de ligação ao antígeno do papilomavírus anti-humano (hpv) e seus métodos de uso
|
EP3967765A1
(en)
|
2017-07-06 |
2022-03-16 |
FrieslandCampina Nederland B.V. |
Cell culture process for making a glycoprotein
|
JP7304846B2
(ja)
|
2017-07-24 |
2023-07-07 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
抗cd8抗体およびその使用
|
TWI799432B
(zh)
|
2017-07-27 |
2023-04-21 |
美商再生元醫藥公司 |
抗ctla-4抗體及其用途
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
WO2019079494A1
(en)
*
|
2017-10-18 |
2019-04-25 |
Regenxbio, Inc. |
TREATMENT OF OCULAR DISEASES AND METASTATIC COLON CANCER WITH A VEGF TRAP WITH HUMAN POST-TRANSLATIONAL MODIFICATION
|
HRP20221335T1
(hr)
|
2017-11-30 |
2022-12-23 |
Regeneron Pharmaceuticals, Inc. |
Upotreba antagonista vegf za liječenje angiogenih očnih poremećaja
|
CA3084155A1
(en)
|
2017-12-13 |
2019-06-20 |
Regeneron Pharmaceuticals, Inc. |
Devices and systems for chromatography column bed support management and related methods
|
US20190194298A1
(en)
|
2017-12-22 |
2019-06-27 |
Regeneron Pharmaceuticals, Inc. |
System and method for characterizing drug product impurities
|
WO2019147944A1
(en)
|
2018-01-26 |
2019-08-01 |
The Regents Of The University Of California |
Methods and compositions for treatment of angiogenic disordres using anti-vegf agents
|
KR20200115485A
(ko)
|
2018-01-31 |
2020-10-07 |
리제너론 파마슈티칼스 인코포레이티드 |
약물 생성물 불순물을 특성화하기 위한 시스템 및 방법
|
TWI825066B
(zh)
|
2018-02-01 |
2023-12-11 |
美商再生元醫藥公司 |
治療性單株抗體之品質屬性的定量及模型化
|
TWI786265B
(zh)
|
2018-02-02 |
2022-12-11 |
美商再生元醫藥公司 |
用於表徵蛋白質二聚合之系統及方法
|
BR112020013426A2
(pt)
|
2018-02-28 |
2020-12-01 |
Regeneron Pharmaceuticals, Inc. |
métodos para identificação de um vírus em uma amostra e para detecção de ácidos nucleicos virais em uma amostra de cultura de células
|
PL3768709T3
(pl)
|
2018-03-19 |
2024-05-20 |
Regeneron Pharmaceuticals, Inc. |
Analizy mikroczipowej elektroforezy kapilarnej i stosowane w nich odczynniki
|
WO2019197676A1
(en)
|
2018-04-13 |
2019-10-17 |
Ludwig Institute For Cancer Research Ltd |
Heterodimeric inactivatable chimeric antigen receptors
|
MX2020011487A
(es)
|
2018-04-30 |
2020-12-07 |
Regeneron Pharma |
Anticuerpos y moleculas biespecificas de union al antigeno que se unen a her2 y/o aplp2, conjugados y usos de estos.
|
TWI814812B
(zh)
|
2018-05-02 |
2023-09-11 |
美商里珍納龍藥品有限公司 |
用於評估生化過濾器的適合性的方法
|
TW202016125A
(zh)
|
2018-05-10 |
2020-05-01 |
美商再生元醫藥公司 |
用於定量及調節蛋白質黏度之系統與方法
|
SG11202010684YA
(en)
|
2018-05-10 |
2020-11-27 |
Regeneron Pharma |
High concentration vegf receptor fusion protein containing formulations
|
US11519020B2
(en)
|
2018-05-25 |
2022-12-06 |
Regeneron Pharmaceuticals, Inc. |
Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
|
TW202005985A
(zh)
|
2018-06-21 |
2020-02-01 |
美商再生元醫藥公司 |
用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症的方法
|
TW202005694A
(zh)
|
2018-07-02 |
2020-02-01 |
美商里珍納龍藥品有限公司 |
自混合物製備多肽之系統及方法
|
WO2020036845A1
(en)
|
2018-08-13 |
2020-02-20 |
Regeneron Pharmaceuticals, Inc. |
Therapeutic protein selection in simulated in vivo conditions
|
SG11202011969WA
(en)
|
2018-08-30 |
2020-12-30 |
Regeneron Pharma |
Methods for characterizing protein complexes
|
EP3870602A1
(en)
|
2018-10-23 |
2021-09-01 |
Regeneron Pharmaceuticals, Inc. |
Ny-eso-1 t cell receptors and methods of use thereof
|
EP3877399A4
(en)
|
2018-11-06 |
2022-10-19 |
Alsatech, Inc. |
CELL-BASED GENE THERAPY FOR NEURODEGENERATIVE DISEASES
|
HUE061783T2
(hu)
|
2019-01-16 |
2023-08-28 |
Regeneron Pharma |
Módszerek diszulfidkötések jellemzésére
|
EP3914914A1
(en)
|
2019-01-25 |
2021-12-01 |
Regeneron Pharmaceuticals, Inc. |
Protein a chromatography - electrospray ionization mass spectrometer
|
BR112021014427A2
(pt)
|
2019-01-25 |
2021-09-28 |
Regeneron Pharmaceuticals, Inc. |
Quantificação e identificação de dímeros em coformulações
|
CN113412121A
(zh)
|
2019-02-12 |
2021-09-17 |
瑞泽恩制药公司 |
使用双特异性抗体结合补体和靶抗原的组合物和方法
|
MX2021010114A
(es)
|
2019-02-21 |
2021-12-10 |
Regeneron Pharma |
Métodos para tratar el cáncer ocular mediante el uso de anticuerpos anti-met y moléculas de unión a antígeno bispecíficas que se unen a met.
|
KR20210136071A
(ko)
|
2019-03-06 |
2021-11-16 |
리제너론 파아마슈티컬스, 인크. |
암을 치료하는데 있어서 증진된 효능을 위한 il-4/il-13 경로 억제제
|
CN114144672A
(zh)
|
2019-04-17 |
2022-03-04 |
瑞泽恩制药公司 |
宿主细胞蛋白质的鉴定
|
US10961500B1
(en)
|
2019-04-23 |
2021-03-30 |
Regeneron Pharmaceuticals, Inc. |
Cell culture medium for eukaryotic cells
|
TW202106699A
(zh)
|
2019-04-26 |
2021-02-16 |
美商愛德維仁生物科技公司 |
用於玻璃體內遞送之變異體aav蛋白殼
|
US20200363400A1
(en)
|
2019-05-13 |
2020-11-19 |
Regeneron Pharmaceuticals, Inc. |
Competitive Ligand Binding Assays
|
EP3969040A1
(en)
|
2019-05-13 |
2022-03-23 |
Regeneron Pharmaceuticals, Inc. |
Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
|
JP2022537019A
(ja)
|
2019-06-21 |
2022-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Psmaおよびcd3に結合する二重特異性抗原結合分子の4-1bb共刺激と組み合わせての使用
|
WO2020257604A1
(en)
|
2019-06-21 |
2020-12-24 |
Regeneron Pharmaceuticals, Inc. |
Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation
|
CN110343666B
(zh)
*
|
2019-07-10 |
2023-05-30 |
通化东宝药业股份有限公司 |
一种cho细胞培养的补料培养基及其制备方法和应用
|
EP4031574A1
(en)
|
2019-09-16 |
2022-07-27 |
Regeneron Pharmaceuticals, Inc. |
Radiolabeled met binding proteins for immuno-pet imaging
|
US11814428B2
(en)
|
2019-09-19 |
2023-11-14 |
Regeneron Pharmaceuticals, Inc. |
Anti-PTCRA antibody-drug conjugates and uses thereof
|
EP4034870A1
(en)
|
2019-09-24 |
2022-08-03 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for chromatography use and regeneration
|
US11912784B2
(en)
|
2019-10-10 |
2024-02-27 |
Kodiak Sciences Inc. |
Methods of treating an eye disorder
|
WO2021108548A1
(en)
|
2019-11-25 |
2021-06-03 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous emulsions
|
KR20220104756A
(ko)
|
2019-11-25 |
2022-07-26 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
안구내 신생혈관형성을 위한 장기지속형 vegf 억제제
|
PE20221790A1
(es)
|
2019-12-06 |
2022-11-25 |
Regeneron Pharma |
Composiciones de proteina anti-vegf y metodos para producir la misma
|
KR20220110555A
(ko)
*
|
2019-12-06 |
2022-08-08 |
리제너론 파마슈티칼스 인코포레이티드 |
Vegf 미니-트랩 및 그의 사용 방법
|
WO2021123908A1
(en)
|
2019-12-20 |
2021-06-24 |
Ludwig Institute For Cancer Research Ltd |
Car-t cell therapy targeting ngcgm3
|
US11835527B2
(en)
|
2020-01-21 |
2023-12-05 |
Regeneron Pharmaceuticals, Inc. |
Deglycosylation methods for electrophoresis of glycosylated proteins
|
US20230060095A1
(en)
|
2020-01-24 |
2023-02-23 |
Regeneron Pharmaceuticals, Inc. |
Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
|
WO2021174151A1
(en)
|
2020-02-27 |
2021-09-02 |
Regeneron Pharmaceuticals, Inc. |
Methods of reducing polysorbate degradation in drug formulations
|
JP2023515941A
(ja)
|
2020-02-28 |
2023-04-17 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Her2に結合する二重特異性抗原結合分子およびその使用方法
|
EP4114859A1
(en)
|
2020-03-06 |
2023-01-11 |
Regeneron Pharmaceuticals, Inc. |
Anti-gitr antibodies and uses thereof
|
EP4127729A1
(en)
|
2020-03-30 |
2023-02-08 |
Regeneron Pharmaceuticals, Inc. |
Methods for characterizing low-abundance host cell proteins
|
KR20230008830A
(ko)
*
|
2020-05-08 |
2023-01-16 |
리제너론 파마슈티칼스 인코포레이티드 |
Vegf 트랩 및 미니-트랩 및 안구 장애 및 암의 치료 방법
|
JP2023530187A
(ja)
|
2020-06-22 |
2023-07-13 |
イノベント バイオロジクス(スーチョウ)カンパニー,リミティド |
抗ang-2抗体とその用途
|
IL299153A
(en)
|
2020-07-13 |
2023-02-01 |
Regeneron Pharma |
Camptothecin analogs conjugated to a glutamine residue in protein, and their uses
|
EP4183415A4
(en)
|
2020-07-16 |
2024-07-17 |
Raqualia Pharma Inc |
TRPV4 INHIBITOR AS THERAPEUTIC DRUG FOR EYE DISEASE
|
CA3176556A1
(en)
|
2020-07-16 |
2022-01-20 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
WO2022047108A1
(en)
|
2020-08-31 |
2022-03-03 |
Regeneron Pharmaceuticals, Inc. |
Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
|
EP4222171A1
(en)
|
2020-10-02 |
2023-08-09 |
Regeneron Pharmaceuticals, Inc. |
Combination of antibodies for treating cancer with reduced cytokine release syndrome
|
IL301702A
(en)
|
2020-10-22 |
2023-05-01 |
Regeneron Pharma |
Anti-FGFR2 antibodies and methods of using them
|
AU2021377185A1
(en)
|
2020-11-10 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Selenium antibody conjugates
|
AU2021385363A1
(en)
|
2020-11-25 |
2023-06-08 |
Regeneron Pharmaceuticals, Inc. |
Sustained release formulations using non-aqueous membrane emulsification
|
AU2021401301A1
(en)
|
2020-12-17 |
2023-08-03 |
Regeneron Pharmaceuticals, Inc. |
Fabrication of protein-encapsulating microgels
|
CA3202197A1
(en)
|
2021-01-20 |
2022-07-28 |
Reginald Smith |
Methods of improving protein titer in cell culture
|
US12030935B2
(en)
|
2021-01-25 |
2024-07-09 |
Regeneron Pharmaceuticals, Inc. |
Anti-PDGF-B antibodies and pharmaceutical composition thereof
|
US20240034796A1
(en)
|
2021-02-04 |
2024-02-01 |
Genuv Inc. |
Anti-pd-1 antibody and use thereof
|
MX2023009279A
(es)
|
2021-02-11 |
2023-10-02 |
Regeneron Pharma |
Metodos de tratamiento de cancer mediante la administracion de un inhibidor de pd-1 como neoadyuvante.
|
CA3170733A1
(en)
|
2021-02-23 |
2022-09-01 |
Petra RIETSCHEL |
Methods of treating lung cancer by administering a pd-1 inhibitor
|
TW202246325A
(zh)
|
2021-03-03 |
2022-12-01 |
美商再生元醫藥公司 |
用於定量及修飾蛋白質黏度之系統及方法
|
WO2022204672A1
(en)
|
2021-03-23 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
|
WO2022204728A1
(en)
|
2021-03-26 |
2022-09-29 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for developing mixing protocols
|
TW202313096A
(zh)
|
2021-05-28 |
2023-04-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
衣殼變異的重組腺相關病毒及其應用
|
MX2023014246A
(es)
|
2021-06-01 |
2024-01-17 |
Regeneron Pharma |
Ensayos y reactivos de microchips de electroforesis capilar.
|
KR20240024061A
(ko)
|
2021-06-22 |
2024-02-23 |
리제너론 파마슈티칼스 인코포레이티드 |
항-EGFRvIII 항체 약물 접합체 및 이의 용도
|
US20230045769A1
(en)
|
2021-07-13 |
2023-02-09 |
Regeneron Pharmaceuticals, Inc. |
Mass spectrometry-based strategy for determining product-related variants of a biologic
|
WO2023287821A1
(en)
|
2021-07-13 |
2023-01-19 |
Regeneron Pharmaceuticals, Inc. |
Characterization of proteins by anion-exchange chromatography mass spectrometry (aex-ms)
|
AR127006A1
(es)
|
2021-09-08 |
2023-12-06 |
Regeneron Pharma |
UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
|
EP4402475A1
(en)
|
2021-09-14 |
2024-07-24 |
Regeneron Pharmaceuticals, Inc. |
Nmass spectrometry-based strategy for characterizing high molecular weight species of a biologic
|
AU2022354864A1
(en)
|
2021-09-28 |
2024-03-07 |
Regeneron Pharmaceuticals, Inc. |
Assays to quantitate drug and target concentrations
|
CN118076894A
(zh)
|
2021-10-07 |
2024-05-24 |
里珍纳龙药品有限公司 |
pH建模和控制的***及方法
|
AU2022359898A1
(en)
|
2021-10-07 |
2024-03-21 |
Regeneron Pharmaceuticals, Inc. |
Ph meter calibration and correction
|
WO2023076340A1
(en)
|
2021-10-26 |
2023-05-04 |
Regeneron Pharmaceuticals, Inc. |
Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
|
KR20240095300A
(ko)
|
2021-11-01 |
2024-06-25 |
리제너론 파아마슈티컬스, 인크. |
Ms-기반 프로테오믹스를 위하여 디술피드 스크램블링을 방지하는 방법
|
WO2023081925A1
(en)
|
2021-11-08 |
2023-05-11 |
Immatics Biotechnologies Gmbh |
Adoptive cell therapy combination treatment and compositions thereof
|
US20230235089A1
(en)
|
2021-11-24 |
2023-07-27 |
Regeneron Pharmaceuticals, Inc. |
Methods for Treating Cancer with Bispecific Anti-CD3 x MUC16 Antibodies and Anti-CTLA-4 Antibodies
|
IL313159A
(en)
|
2021-12-01 |
2024-07-01 |
Kadmon Corp Llc |
B7-H4 antibodies and ANTI-B7-H4 antibody/IL-15 fusion proteins
|
CA3241734A1
(en)
|
2022-01-12 |
2023-07-20 |
Amy Han |
Camptothecin analogs conjugated to a glutamine residue in a protein, and their use
|
WO2023177836A1
(en)
|
2022-03-18 |
2023-09-21 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for analyzing polypeptide variants
|
WO2023196903A1
(en)
|
2022-04-06 |
2023-10-12 |
Regeneron Pharmaceuticals, Inc. |
Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
US20240148867A1
(en)
|
2022-10-31 |
2024-05-09 |
Regeneron Pharmaceuticals, Inc. |
Methods of treating cancer with a combination of adoptive cell therapy and a targeted immunocytokine
|
WO2024118785A2
(en)
|
2022-11-30 |
2024-06-06 |
Regeneron Pharmaceuticals, Inc. |
Tlr7 agonists and antibody-drug-conjugates thereof
|
WO2024130048A1
(en)
|
2022-12-16 |
2024-06-20 |
Regeneron Pharmaceuticals, Inc. |
Methods and systems for assessing chromatographic column integrity
|
WO2024137731A2
(en)
|
2022-12-21 |
2024-06-27 |
Genzyme Corporation |
Anti‑pd‑1×4‑1bb binding proteins
|
WO2024138000A1
(en)
|
2022-12-21 |
2024-06-27 |
Regeneron Pharmaceuticals, Inc. |
Prodrugs of topoisomerase i inhibitor for adc conjugations and methods of use thereof
|